A Review of Achromatopsia

Sandra Abeijón Martínez*

School of Advanced Education, Research and Accreditation (SAERA)

*Corresponding author: Sandra Abeijón Martínez, School of Advanced Education, Research and Accreditation (SAERA)

Received: September 02, 2020
Published: September 21, 2020

Introduction

Achromatopsia is a condition characterized by a partial or total absence of color vision [1]. People with complete achromatopsia cannot perceive any colors; they only see white, black, and shades of gray. Incomplete achromatopsia is a milder form of the disease that allows some color discrimination [1]. Oliver Sacks, in The Case of Color-blind Painter [2], transcribe the disturbing story of one of his cerebral achromatopsia patients after a car accident in the following way: Mr. I. could hardly tolerate the changed aspects of people (“like animated grey statues”) any more than he could tolerate his own appearance in the mirror: he shunned social intercourse and found sexual intercourse impossible. He saw people’s fesh, his wife’s fesh, his own fesh, as an abhorrent grey; “fesh-colored” now appeared “rat-colored” to him. Congenital achromatopsia also involves other problems with vision, including an increased sensitivity to light and glare (photophobia), involuntary back-and-forth eye movements (nystagmus), significantly reduced sharpness of vision (low visual acuity) [1], usually lower than 20/200 because of central vision loss, and reduced conemediated electroretinographic (ERG) amplitudes [3]. Affected individuals can also have vision problems in the first few months of life, such as hyperopia (farsightedness) or, less commonly, myopia (nearsightedness).

Achromatopsia is different from the more typical forms of color vision deficiency (also called color blindness), in which people can perceive color but have difficulty distinguishing between specific colors, such as red and green [1]. In this disease, cone photoreceptors, the retinal sensory neurons mediating color vision, seem viable but fail to generate an electrical response to light [4,5]. All individuals with achromatopsia (achromats) have impaired color discrimination along all three axes of color vision corresponding to the three cone classes [6]. Cerebral achromatopsia is an acquired disorder caused by injury to the cerebral cortex of the brain, instead of defectiveness in the cells of the eye’s retina. This condition is often

Abstract

Congenital achromatopsia is a hereditary form of day blindness caused by cone photoreceptor dysfunction, with an incidence of approximately 1 in 30,000. This inherited disorder is characterized by a lack of color discrimination, nystagmus, photophobia, and low visual acuity (< 0.2). The most typical genetic mutations are autosomal recessive changes in CNGA3, CNGB3, GNAT2, PDE6H, PDE6C, or ATF6. It should not be confused with cerebral achromatopsia, which is an acquired form of total color blindness that can result from illness, trauma, or some other cause. Color plays an essential role in our lives. It can change actions, influence thinking, and cause reactions. As a powerful type of communication, color is irreplaceable. Green means “go” and red means “stop”. Traffic lights send this global meaning. Color vision deficiency, creates challenges in the daily lives of those who have an insufficient visual sense.

Purpose: The aim of this review is to examine the literature published on achromatopsia and summarize the diagnosis, management, genetic characteristics, and the recent advances in gene therapy.

Conclusions: Congenital achromatopsia is a complex inherited disease. Management of achromatopsia is multifaceted. There is currently no cure for achromatopsia, although gene therapy is a therapeutic option already being studied in clinical trials. The most recent study in human adults can be classified as safe and positive in terms of efficacy.

Keywords: Achromatopsia (ACHM); Gene therapy
mistaken for congenital achromatopsia but physiological deficits of both disorders are completely different. It is a consequence of cortical damage that arises through ischemia or infarction of a specific area in the ventral occipitotemporal cortex of humans [7]. This damage is almost always the result of injury or illness [8]. Medical history and age at presentation will help to differentiate this condition from congenital achromatopsia. Additionally, these patients nearly always have additional neurologic symptoms beyond the loss of color vision [8].

Epidemiology

Achromatopsia is a relatively uncommon disorder that affects an estimated 1 in 30,000 people worldwide [9]. Complete achromatopsia is more common than incomplete achromatopsia. Its incidence varies in different parts of the world. Because there is a genetic link, it is more common in regions where there is a high rate of consanguineous marriages (marriages between relatives) and in the eastern Pacific islands of Pingelap [10], approximately five percent of the atoll’s 3,000 inhabitants are afflicted [11,12]. The people of this region have termed achromatopsia “maskun”, which literally means “not see” in Pingelapese [13]. The condition can be traced back to 1775, when Typhoon Lengkieki decimated the population in the island, leaving only a handful of survivors to repopulate the islands. One of the few survivors was a carrier of the rare genetic mutation and passing it on to his descendants, he became the genetic founder for the vision disorder four generations later [14]. Oliver Sacks wrote his book, The Island of the Colorblind (1997), which story chronicles Oliver Sack’s 1994 quest with Knut Nordby and Bob Wasserman to the isolated atoll of Pingelap in Micronesia.

Photoreceptors: rods and cones

Figure 1: Schematic diagram of vertebrate rod and cone photoreceptors. Retrieved from Photoreceptor Phosphodiesterase (PDE6): A G-Protein-Activated PDE Regulating Visual Excitation in Rod and Cone Photoreceptor, Cells Rick H Cote 2006.
Rod and cone photoreceptors are specialized neurons that function in the initial step of vision [15]. These light-sensitive cells lie at the back of the retina adjacent to the retinal pigment epithelium (RPE), a cell layer that is vital for the survival of photoreceptors [15]. Cones are mostly in the center of the retina. When retinitis pigmentosa affects them, there is a slowly loss of central vision and of the ability to see colors [15]. Rods work at very low levels of light. Only a few bits of light (photons) can activate a rod, that’s why we use these for night vision. Rods don’t help with color vision, which is why at night, we see everything in a gray scale [16]. Rods are more numerous, about 120 million, and more sensitive than cones. However, they are not sensitive to color. Rods are much more concentrated in the macula (central yellow spot) and they provide the eye’s color sensitivity. In the center of the macula is the “fovea centralis”, a 0.3 mm diameter rod-free area with densely packed and very thin cones. Rod and cone photoreceptors have similar structures (Figure 1). Photoreceptors have diameters ranging from 1 to 4 µm, being smaller at the fovea, enhancing visual acuity there. The inner segment contains the nucleus and has an axon-like process connected to a synaptic terminal. The outer segment in the cone cell has its plasma membrane invaginated into numerous closely packed parallel folds [17], forming discs. In rod cells the discs are pinched off the plasma membrane to become completely intracellular [17]. The disc membrane is densely packed with visual pigment. In rod cells, this is rhodopsin. Each type of cone cells has its characteristic cone opsin. The outer segment is continually regenerated from the base, whilst its apical tip is phagocytosed by pigment epithelial cells at the rate of 3-4 discs per hour. Photoreceptors are incapable of mitotic division [17].

In 1965 came experimental confirmation of a long-expected result - there are three types of color-sensitive cones in the retina of the human eye, red or L cones (long wavelength-64%), green or M cones (medium wavelength-32%), and blue or S cones (short wavelength-2%). They are each sensitive to different portions of the spectrum of light. Visible colors correspond to light wavelengths ranging from 400 to 700 nm [16]. Even though each cone is most sensitive to a specific color of light (where the line peaks), they also can detect other colors (Figure 2) [16].

The “blue” cones are sensitive to the peak of the light response curve at about 445nm. They are found outside the fovea centralis where the green and red cones are concentrated and they constitute only about 2% of the total number of cones. Their disadvantage in number is clear but, on the contrary, they are much more light sensitive than green and red cones [18]. However, the blue sensitivity of the final visual perception is equivalent to that of red and green, proposing that there is a somewhat selective “blue amplifier” somewhere in the visual processing in the brain [18]. Morphological studies have allowed us to differentiate the short wavelength specific (blue) cone from the medium and long wavelength specific cones in the human retina even without special antibody staining techniques [19]. S-cones have longer inner segments that project further into subretinal space than longer wavelength cones (Figure 3).

The S-cones also have smaller and morphologically different pedicles than the other two wavelength cones. Throughout the retina, the S-cones have a different distribution and do not fit into the regular hexagonal mosaic of cones typical of the other two types [20].

**Figure 2:** The three types of cones, capable of recognizing light wavelengths that peak at green, red and blue. Retrieved from Rods and Cones, C J Kazilek, Kim Cooper 2010.
Different kinds of color blindness

Most of us have the ability to perceive a million different colors [21]. This is due to the presence of the three types of cones in our eyes that send color messages to our brain. Some people who have a faulty cone or only two cones can suffer a greatly decreased color perception. This condition is known as color blindness [21].

That color vision is trichromatic was first recognized by Thomas Young at the beginning of the nineteenth century (thus, people with normal color vision are called trichromats). Trichromats have normal cones and light sensitive pigment and they can see all the different colors and delicate mixtures of them by using cones sensitive to one of three light wavelengths (red, green, and blue). Monochromacy and Achromatopsia, also known as “total color blindness” [22], is the lack of ability to distinguish colors; caused by cone defect or absence [23]. Monochromacy occurs when two or all three of the cone pigments are missing and color and lightness vision is reduced to one dimension [22].

Cases of achromatopsia are classified as complete when the patient has a total loss of color discrimination or incomplete when this loss of color discrimination is partial. The variability across this spectrum is believed to be due, in part, to the degree of residual cone photoreceptor function. Patients with complete achromatopsia have a total absence of color discrimination, and they are only able to perceive white, black, and shades of gray. Complete achromatopsia is caused by the total loss of function of all three types of cone photoreceptors (long-wavelength, medium-wavelength, and short-wavelength) [24] (Figure 4).
Patients with incomplete achromatopsia have better color discrimination and visual acuity, in comparison to patients with complete achromatopsia. Some patients with incomplete achromatopsia have particular types of color vision impairment, such as loss of photoreceptor function in medium-wavelength cones but residual function in short-wavelength and long-wavelength cones [24,25]. This example of incomplete achromatopsia is associated with deuteranopia-like green color blindness, but it is distinct from true X-linked deuteranopia’s, which are caused by mutations in the gene that encodes medium-wavelength-sensitive opsin [26]. Achromatopsia and Monochromacy describes a range of conditions that include Achromatopsia, rod-Monochromacy and S-cone Monochromacy. Sometimes, these are collectively referred to as types of achromatopsia, as the word “achromat” meaning “no color” [27]. However, not all cases of achromatopsia have “no color” vision. Trichromats, Dichromats and Monochromats are terms used in the vision science community to refer to different possible configurations of the human visual system having three (tri-), di (two) or one (mono) channel of color information [27]. People with dichromatic color vision have only two types of cones which are able to perceive color, that is, they have a total absence of function of one cone type [28]. Lack of ability to see color is the simplest way to explain this condition but in actual fact it is a specific section of the light spectrum which can't be perceived. For convenience we call these areas of the light spectrum ‘blue’, ‘green’ or ‘red’. The sections of the light spectrum which the ‘green’ and ‘red’ cones perceive overlap and this is why green and red color vision deficiencies are often known as red/green color blindness and why people with red and green deficiencies see the world in a similar way [28]. Dichromats exist in three different types according to the missing cone: protanopia (missing L-cone red), deuteranopia (missing M-cone green), and tritanopia (missing S-cone blue) (Figures 5 & 6).

**Figure 5:** Simulation of colorblind vision. Retrieved from Color Universal Design (CUD) How to make figures and presentations that are friendly to Colorblind people, Okabe and Ito 2008.

**Figure 6:** Simulation of colorblind vision 2016.
People with ‘defective’ trichromatic vision will be color blind to some degree and are known as anomalous trichromats. In people with this disorder all of their three cone types are used to perceive light colors but one type of cone perceives light slightly out of alignment, so that there are three different types of effect produced depending upon which cone type is ‘defective’ [28]. The different anomalous conditions are protanomaly, which is a diminished sensitivity to red light, deuteranomaly which is a diminished sensitivity to green light and is the most usual form of color blindness and tritanomaly which is a diminished sensitivity to blue light and is extremely rare [28]. About half of people with anomalous trichromacy will see the world in a similar way to those with dichromacy but their capacity to perceive colors will worsen in poor light and improve in good light. Often their color perception can be as poor as it is for those with dichromacy [28] (Figure 7).

Figure 7: Color vision deficiencies can be either due to a mutation that shifts one of the color cones or a lack of one of them. The affected color cone can be red (protan), green (deutan) or blue (tritan). Figured adapted from Okatobe and Ito 2008.

Tetrachromatic color vision allows an individual to discriminate colors along a perceptual dimension that is unavailable to the normal person. Most people’s color perception is “trichromatic” [29]. Organisms with tetrachromacy are called tetrachromats. For these organisms, the perceptual effect of any arbitrarily chosen light from its visible spectrum can be matched by a mixture of no fewer than four different pure spectral lights [30]. The normal explanation of tetrachromacy is that the organism’s retina contains four types of cone cells with different absorption spectra [30]. This means the animal may see wavelengths beyond those of a typical human being’s eyesight, and may be able to differentiate colors that to a human are identical. However, the relationship between the existence of a fourth class of retinal cone and the dimensionality of color vision is more complex than previously thought [29]. The zebrafish (Danio rerio) is an example of a tetrachromat, containing cone cells sensitive for red, green, blue, and ultraviolet light [31]. Tetrachromacy is expected to occur in several species of birds, fish, amphibians, reptiles, arachnids, and insects.

Phototransduction

Phototransduction is a process by which light is converted into electrical signals in the rod cells, cone cells and photosensitive ganglion cells of the retina of the eye. The visual cycle is the biological transformation of photons into an electrical signal in the retina. This process occurs through G-protein coupled receptors called opsins which contain the chromophore 11-cis retinal. 11-cis retinal is the chromophore present in all photoreceptors; it is a derivative of vitamin A [32]. Phototransduction in rods is initiated when light isomerizes the 11-cis-retinal chromophore of rhodopsin to its all-trans isomer that induces a conformational change [33-36]. 11-cis retinal is covalently linked to the opsin receptor via Schiff base forming retinylidene protein. Opsin therefore undergoes a conformational change to metarhodopsin II, which activates the regulatory G protein transducin (Gt). The alpha subunit of Gt activates phosphodiesterase, also known as PDE6, which hydrolyses cGMP to 5’-GMP. As high level of cGMP keeps cGMP-gated sodium channels open, the lowering of cGMP levels closes these channels [37] which causes hyperpolarization of the cell due to the ongoing efflux of potassium ions. Subsequently, hyperpolarization of the cell causes closure of voltage-gated calcium channels. As calcium levels in the photoreceptor cell drop, the level of the neurotransmitter glutamate also drops. This is because calcium is necessary for the glutamate-containing vesicles to fuse with the cell membrane and liberate their contents. A decrease in the amount of glutamate liberated by the photoreceptors causes hyperpolarization of cone off-center bipolar cells and depolarization of on-center bipolar cells (rod and cone On bipolar cells). This effectively relays the light signal to postsynaptic neurons as an electrical signal [38-43] (Figures 8 & 9).
Causes

Achromatopsia can be acquired or congenital. Brain damage can produce acquired deficiencies of color perception, or cerebral achromatopsia. Cerebral achromatopsia is a type of acquired color blindness that is caused by damage to the cerebral cortex of the brain, rather than defectiveness in the cells of the eye’s retina. In patients with cerebral achromatopsia, lesions tend to overlap on a restricted region in the ventral occipitotemporal cortex, close to the reported locations of the putative V4 complex and to foci of increased blood-oxygen-level-dependent (BOLD) activity related to color perception in normal participants [44]. As an only sequel to a
Achromatopsia is characterized by a pendular nystagmus, reduced visual acuity, a small central scotoma, eccentric fixation, an increased sensitivity to light (photophobia) and reduced or complete loss of color discrimination. All achromats have impaired color discrimination along all three color vision axes, each one corresponding to the three cone classes. These symptoms usually start at birth or early infancy and their severity varies depending on genetic and phenotypic variability. Visual acuity is usually less than 20/200 for those with complete achromatopsia but may be as good as 20/80 for those with incomplete achromatopsia. Visual acuity is usually stable [60], in contrast to other cone dystrophies in which visual acuity progressively worsens.

Clinically, the first signs of achromatopsia in infants are the presence of nystagmus, a pendular quivering of the eyes, and photophobia as evidenced by squinting in bright light [60]. In usual complete achromatopsia, patients present typically by 6 months old with nystagmus and photophobia. As one example, many achromats have been given the diagnosis of “congenital nystagmus.” Nystagmus (involuntary movement of the eyes) is a symptom of achromatopsia, one that is especially obvious during infancy and childhood, but having this symptom is not the same as having the medical eye condition which is known as “congenital nystagmus” [61]. Nystagmus and sensitivity to bright light may improve faintly. Moreover, children may show paradoxical constriction of the pupil in the dark, commonly have high hyperopic refractive errors (need for plus power glasses). Although the fundus is usually normal, in some affected individuals may be present macular changes and vessel narrowing, retinal pigment epithelium disturbances (separated into three categories: presence of retinal pigment epithelium disturbance [50%), no retinal pigment epithelium disturbance [27.5%], and atrophy [22.5%]). [62] or alteration of the foveal reflex [63].

Diagnosis

The diagnosis of ACHM is established in a proband through clinical and family history, examination for visual acuity testing, nystagmus, fundoscopic examination, and color vision assessment. If ACHM is suspected, supplementary tests will be recommended, such as optical coherence tomography, fundus autofluorescence, visual fields, and electroretinogram. Identification of biallelic pathogenic variants in , CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, or ATF6 verify the clinical diagnosis. The family history is useful to orientate the diagnosis by the inheritance mode. Family trees are useful in these cases [64]. Visual field examination usually demonstrates small central scotomas by careful testing, but this test can be difficult to perform due to a lack of steady fixation [63]. The color perception of individuals with achromatopsia (achromats) is unreliable; many achromats learn to associate certain colors with objects and to recognize some colors by discerning differences in brightness [65]. Patients with achromatopsia demonstrate defectiveness in all three axes of color vision. The most important and diagnostic tests include the Rayleigh anomaloscope (which is
the most reliable test), Farnsworth Munsell 100-Hue, and Panel D-15 tests [66]. The most common electrophysiology tests used in the diagnosis of achromatopsia are electroretinogram and visual-evoked potentials [67,68]. This technique sometimes fails to show pathologic changes in cases of achromatopsia due to a limited number of photoreceptors within the fovea compared to the entire retina [64]. A full-field ERG evaluates the whole retina. The photopic response (including the 30-Hz flicker response) is absent or notably diminished; the scotopic response is normal or slightly abnormal. Genead [69] found that 75% of patients with achromatopsia showed normal responses in this test.

Optical coherence tomography (OCT) is a great instrument for the imaging and study of different structures in the eye. Achromatopsia has also been studied with macular OCT [62]. Several clinical studies in recent years have investigated outer retinal architecture and foveal morphology in detail using high-resolution optical coherence tomography (OCT) and adaptive optics [62,70-77].

Sundaram categorized ACHM patients into the following five groups based on outer retinal OCT findings [62].

- a) continuous inner segment ellipsoid (Ise) (appeared in 22.5% of the patients studied).
- b) Ise disruption (27.5%).
- c) absent Ise (20%).
- d) foveal hyporeflective zone (22.5%).
- d) outer retinal atrophy (7.5%).

No differences in the age, visual acuity, contrast sensitivity, or retinal sensitivity were found between patients in these five groups [62]. A variable degree of foveal hypoplasia as well as disruption and/or loss of inner-/outer-segment junction of the photoreceptors and an attenuation of the RPE layer within the macular region can be observed at an early age [62,69,72,78,79]. Fundus autofluorescence is a relatively new imaging technique that takes advantage of the autofluorescent properties of lipofuscin to document its accumulation. Fahim described fundus autofluorescence in patients with achromatopsia [80]. Fundus autofluorescence imaging shows missing or variable formation of foveal hypofluorescence or a larger lesion with a surrounding hyperautofluorescent ring and a central region of absent autofluorescence corresponding to the lesion area seen on OCT [47,73]. Genetic testing can be useful for securing the diagnosis, risk assessment in relatives, prenatal diagnosis, and prognosis, and identifying carriers and new affected genes [66]. Molecular genetic testing approaches can include serial single-gene testing, use of a multi-gene panel, and more comprehensive genomic testing [66]. Targeted analysis for the most common pathogenic variant c.1148delC in CNGB3. The order for serial single-gene testing is based on the incidence of pathogenic variants in each gene. A multigene panel includes AT1F6, CNAG3, CNGB3, GNAT2, PDE6C, PDE6H, and other genes of interest. Comprehensive genomic testing includes targeted exome [81], whole-exome, and whole-genome sequencing. This may be considered if other tests have not confirmed the diagnosis.

**Treatment**

There is usually no treatment to cure achromatopsia. In certain circumstances, patients can be worn red-tinted contact lenses or dark or special filter glasses to help reduce photophobia, increase brightness, improve visual acuity, and make it easier to identify colors, but many patients find them disorientating and difficult to wear. Tinted contact lenses supplemented with sunglasses or wrap-around glasses or use of opaque side-shields may also be used [82]. Tinted central contact lenses typically transmitting light at wavelengths between 400-480nm [83] are an improvement over simple cutoff filters in alleviating photophobia [82]. Additionally, these contacts have reduced the stigma of wearing dark wraparound sunglasses indoors. However, such red central contacts only decrease the amount of light entering the retina and do nothing to enhance high-resolution vision or color sensitive tasks. A partial solution is to use tinted contact lenses with magnification to boost what central vision is still present from functional photoreceptors [84]. If jurisdictional laws and visual acuity permit, patients with achromatopsia can drive a car with the use of bio-optics. Management targets symptoms and associated findings, striving to improve quality of life. Achromats frequently improve their own strategy that best works for them. Refractive errors should be checked (need for glasses). Prescribing glasses to correct refractive conditions such as far-sightedness (hyperopia), near-sightedness (myopia) and astigmatism can improve the vision somewhat but will not restore the normal levels of vision [10]. Children with achromatopsia should have preferential seating in the classroom (i.e., in the front to benefit maximally from magnifying devices and away from windows to reduce the effects of glare on vision) [6]. Consultation with low vision services would be valuable and often recommended to find appropriate low vision aids for school, work, or activities of daily living [10]. Psychosocial issues need to be also addressed with the patient and family. Low vision aids include high-powered magnifiers for reading as well as digital/electronic devices. There are small, handheld color detecting tools such as Colorino that allow detection of color for particular activities. These can be used to check the color of clothes. It is a color identifier that can identify more than 150 colors, announcing them in a clear voice in 20 different languages.

A newer device known as the Eyeborg system can help people with no color vision to perceive color through sound waves. Artist...
Neil Harbisson who suffered from achromatopsia was one of the first to use this device in early 2004 [10]. The color sensor in the Eyeborg detects colors, and then converts them to sounds, based on how high or low the pitch of the sound can provide a way to determine the color. Enormous efforts have been made in recent years to develop a possible cure for ACHM, and the new gene replacement therapeutic approaches are promising [85]. A specific vector is always required to deliver the target gene into the cell because DNA alone is not able to complete the task. Vector choice depends on the size of the cDNA of the type of targeted cells, the relevant gene, stability of expression, and immunogenicity [86]. Ongoing studies in mice, primates, and canines using adeno-associated virus (AAV) as vectors for gene therapy [86], have shown great promise. Three clinical Phase I/II safety trials for gene replacement therapy using aden-associated viral vectors for achromatopsia association with CNGA3 and CNGB3 have been approved. A team from the Institute for Ophthalmic Research at the University Hospitals in Tübingen and the Departments of Pharmacy and Ophthalmology at LMU has developed a treatment that should, in principle, correct the CNGA3 genetic defect [87]. It involves introducing the normal version of the CNGA3 gene directly into the patient’s retina with the aid of a harmless virus, and hopefully the correctly functioning gene begins producing whatever protein was previously missing, helping cure the condition caused by the defective gene. The first clinical study of this approach in patients has just been completed at the University Eye Hospital Tübingen. In this study, nine patients with achromatopsia aged between 24 and 59 years were treated by injection of the virus bearing the intact CNGA3 gene into retina of the more severely affected eye [87]. The treatment can be classified as safe and potentially efficacious. The researchers mention the treatment will likely be most efficient if administered in childhood, as the brain is still highly plastic and the visual cortex has yet to fully develop. It is suggested in the study the ideal age may be before a patient reaches approximately seven years old as, after that point, the visual cortex has mostly developed and the primary structural loss of cone photoreceptors has taken place [88].

Objectives

The purpose of the thesis is to conduct a narrative review of achromatopsia and to examine the literature published to summarize the clinical disease, the genetic characteristics, and the recent advances in gene therapy. Specifically, this review will describe the management strategies with particular interest for the latest advances in gene therapy in humans.

Method of literature search

Study design

A literature review has been carried out to contribute to the scientific literature on achromatopsia and provide a comprehensive review of the clinical disease, the diagnosis and management of patients, and genetic characteristics. By means of a search on Pubmed, Scopus and Medline, 400 articles were obtained. The search was also the internet database for achromatopsia and gene therapy. The first step was oriented to articles published for congenital achromatopsia. The second step was focused on gene therapy achromatopsia. Papers published in any language during the last 20 years were selected. A scoring method regarding the scientific evidence (GRADE) was applied for all chosen manuscripts. Results: only 30 papers were considered as relevant for this review taking into account the research criteria.

Criteria for selection of publications

Inclusion criteria

Scientific articles published from January 2000 to February 2020, available without limitation to the language of their publication with regard to abstracts. Only meta-analyses, systematic reviews of the literature and controlled experimental studies in humans and animals that evaluated the gene therapy, and the diagnosis and management of patients with achromatopsia were selected. Filters like age, race, sex or geographical location were not taken into account.

Exclusion criteria

Articles that did not meet the inclusion criteria mentioned above were rejected.

Selection of articles

The selection of the articles was done analyzing the title, followed by reading the abstract to identify those that would be fully read. The exclusion and inclusion criteria expressed above were applied to the search results.

Results

Genes identified as responsible for ACHM

To date, mutations in six different genes have been identified as responsible for ACHM: CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, and ATF6 (Table 1 & 2).
Table 1: Prevalence of genes implicated in ACHM.

| Genes implicated in ACHM | Study reference and date | Genes implicated in ACHM | Study reference and date | Genes implicated in ACHM | Study reference and date |
|-------------------------|--------------------------|-------------------------|--------------------------|-------------------------|--------------------------|
| CNGB3 (ACHM3)           | Zobor [85]               | 50%                     | CNCA3 (ACHM2)            | Wisinger [49]           | 25%                     |
|                         | Kohl [60,94] Aligianis [56] | 50%                     | GNAT2 (ACHM4)            | Kaupp and Seifert 2002  | 23%                     |
|                         | Kohl [55,94]             | 50%                     | PDE6C (ACHM5)            | Felden [95]             | <2%                     |
|                         | Weischuh [96]            | 50%                     | PDE6H (ACHM6)            |                        | <2%                     |
|                         |                          |                          | ATF6 (ACHM7)             |                        | 2.40%                   |

Table 2: Genes implicated in ACHM.

| GENES | Inheritance pattern | Phenotype | Study reference and date | Encoding |
|-------|---------------------|-----------|--------------------------|----------|
| CNGB3 | Autosomal recessive | Over 40 mutations found to cause ACHM | Kohl [50] Sundin [51] | Encode the β-subunits of the cyclic nucleotide-gated (CNG) cation channel of the cone photoreceptor |
| CNGA3 | Autosomal recessive | Over 100 mutations in this gene have been identified to result in ACHM | Kohl [50] Sundin [51] | Encode the α-subunits of the cyclic nucleotide-gated (CNG) cation channel of the cone photoreceptor |
| GNAT2 | Autosomal recessive | At least 10 mutations found to cause ACHM | Kohl [55] Aligianis [56] | Encode the catalytic α-subunit of the G-protein transducing |
| PDE6C | Autosomal recessive | At least 19 mutations to cause ACHM | Thiadens, Kohl, Chang [56-58] | Encode the catalytic α-subunits of the cone photoreceptor-specific phosphodiesterase |
| PDE6H | Autosomal recessive | S12x mutation prevents production of functional inhibitory gamma subunit | Thiadens, Kohl, Chang [56-58] | Encode the inhibitory γ-subunits of the cone photoreceptor-specific phosphodiesterase |
| ATF6  | Autosomal recessive | ATF6 mutations group into three distinct molecular pathomechanisms | Kohl [47] | Encodes the ubiquitously expressed ATF6, a key regulator of the UPR, and cellular endoplasmic reticulum (ER) homeostasis |

Changes in retinal morphology

Optical coherence tomography (OCT) provides visualization of retinal lamination, enabling measurements of retinal layer thickness and intensity. Of particular interest are the hyperreflective (ellipsoid zone, EZ, and interdigitation, IZ) and hyporeflective (outer nuclear layer, ONL) bands associated with the photoreceptors [89-90]. Another imaging tool, adaptive optics scanning light ophthalmoscopy (AOSLO), enables noninvasive, cellular resolution imaging of the rod and cone photoreceptors mosaic. A confocal detector enables visualization of cones based on their waveguiding ability [91,92]. The waveguiding ability is thought to require intact outer segments [93] (Table 3).

Table 3: EZ, ONL and AOSLO in the different genes identified as responsible for ACHM.

| EZ OCT | ONL OCT | AOSLO |
|--------|---------|-------|
| CNGA3, CNGB3 | Disrupted or absent in about 70% of the cases Sundaram, Langlo [62]. | Significantly reduced Langlo, Georgiou [106]. | Confocal AOSLO: absence of normally waveguiding cone photoreceptors (“dark spaces”). Rod photoreceptor mosaic appears normal Genedal, Langlo, Patterson [69]. Nonconfocal AOSLO: a remnant inner segment structure has been observed in these patients that spatially coincides with the nonwaveguiding cones seen in the confocal image. Langlo 2016; Scoles [74]. |
| GNAT2 | Relatively least disrupted photoreceptor mosaic Ueno, Dibus [77,107]. | Remnant cone function in some patients (Schockman 2007). | |
| ATF6 | EZ absent or hyperreflective zone Mastey [106]. | Hyperreflectivity of the ONL Mastey [106]. | Confocal AOSLO: no evidence of remnant foveal cone structure. Nonconfocal AOSLO: sporadic cone-like structures Mastey [106]. |
Discussion

Clinically, approximately 50% of ACHM patients are associated with CNGB3 mutations, about 25% with CNGA3 mutations and smaller fractions with mutations in the cone transducing or phosphodiesterase genes in European populations [85-94]. GNAT2 mutations account for about 2% [48,49,56,94]. A study from Felden [95] estimated the prevalence of GNAT2-ACHM to be 1.7%, in a cohort of 1116 independent ACHM families [95]. GNAT2, PDE6C, and PDE6H, are each responsible for fewer than 2% of cases [55,94]. A recent study by Weisschuh [96] estimated the prevalence of the PDE6C genotype to be 2.4% in a cohort of 1074 independent ACHM families [96]. Mutations in ATF6 were recently identified in some subjects with ACHM who were negative for mutations in the aforementioned phototransduction genes [97,98]. In the ongoing debate about the stationary or progressive nature of ACHM, different genotypes should be studied individually. Achromatopsia has been classically described as stationary [99-101]; however, several recent studies have suggested it is a progressive condition. Thiadens [71] examined 40 ACHM patients using spectral-domain optical coherence tomography (SD-OCT), and reported that increased cone cell “decay” and retinal thinning was correlated with age, and began in early childhood [71]. Thomas [70], also showed progressive longitudinal changes in retinal morphology in children and described an interesting OCT sign, i.e. a hyperreflective zone which appears to be the precursor of the hyporeflective zone seen in later ages [70]. In contrast to these studies, Genead [69], provided evidence that cone loss is not age dependent [69]. Sundaram [62], examined 40 ACHM patients aged 6 to 52 years, and found no correlation between age and visual acuity, total foveal thickness, foveal ONL thickness, or inner segment ellipsoid (ISe) intensity and cone loss on SD-OCT [62]. Thiadens [71], in a cohort with five patients with PDE6 (20%) and no GNAT2, concluded that ACHM had been often a progressive disease [71]. PDE6C-ACHM was recently reported as a slowly progressive maculopathy [102]. ACHM studies conducted by Hirji [103] and Thiadens [71] with different proportions of patients with GNAT2 and PDE6C have shown conflicting results [71-103]. Hirji [103], in a cohort with one subject with PDE6C (2%) and two subjects with GNAT2 (4%), concluded that ACHM was predominantly stationary [103]. Although the retinal structure seems to show great variety and a slow progressive cone loss has been suggested [62,71,76,104,105], no clear association between retinal structure and function could be described [62]. Therefore, ACHM can be best described as a functional stationary disorder with slow degeneration of cone photoreceptors. Marked variability in the cone mosaic has been observed across patients; among the two most common genotypes, CNGA3 and CNGB3 [62,69,102]. Carroll [75], observed a severely disrupted cone mosaic in the fovea and parafoveal area of a single patient with mutations in CNGB3 [75]. Genead [69], reported residual cone structures in all 9 patients carrying mutations in either CNGA3 or CNGB3, though the majority of cones had a reduced reflectance [69]. In contrast, in ATF6-ACHM and PDE6C-ACHM, few if any residual foveal cones were identified [102-106]. The GNAT2-ACHM genotype is associated with the relatively least disrupted photoreceptor mosaic [77-107].

Conclusion

Achromatopsia is a complex inherited disease. There is currently no approved treatment for ACHM. Management of achromatopsia is multifaceted, including making the appropriate diagnosis, reducing photophobia, correcting refractive error, and utilizing low vision devices, such as high-powered magnifying glasses. To reduce photophobia and potentially improving visual acuity can be helpful use of dark or special filter glasses or red-tinted contact lenses. However, even with the best aid techniques, daily tasks such as going to school and driving present significant obstacles. New diagnostic and therapeutic tools are being studied. Fundus autofluorescence and OCT are important imaging techniques that supply significant information about the progression of the disease. Gene therapy is an ongoing therapeutic option already being studied in clinical trials. The new gene therapy being trialed centers on correcting a defect in the CNGA3 gene. The results of a first human trial testing for achromatopsia suggest that the experimental gene therapy is safe, and potentially efficacious, opening the door to larger human trials in the future. The evidence to date suggests that gene therapy will need to be applied early in childhood in order to achieve the best possible effect. The remarkable advances in genetics have opened an exciting world to ophthalmologists to offer patients new treatments for achromatopsia. In the future, gene therapy will be a routine treatment offered to patients.

References

1. Genetics Home Reference (2015).
2. Sacks O (1995) An Anthropologist on Mars Pp. 340.
3. Pang JJ, Alexander J, Lei B (2010) Achromatopsia as a potential candidate for gene therapy. Adv Exp Med Biol 664: 639-646.
4. Krill AE (1978) Krill’s Hereditary Retinal and Choroidal Diseases. Br J Ophthalmol 62(2): 130-131.
5. Hess RF, Sharpe LT, Nottby K (1990) Total colour blindness. Cambridge: Cambridge University Press. United Kingdom.
6. Kohl S, Jägle H, Wissinger B (2004) Achromatopsia. Gene Review.
7. Jaeger W, Krastel H, Braun S (1988) Cerebral achromatopsia (symptoms, course, differential diagnosis, and strategy of the study). I. Klin Monbl Augenheilkd 195(6): 627-634.
8. Bouvier SE, Engel SA (2006) Behavioral deficits and cortical damage loci in cerebral achromatopsia. Cerebral Cortex 16(2): 183-191.
9. Thiadens AAHJ (2011) Genetic Etiology and Clinical Consequences of Cone Disorders. Erasmus University Rotterdam.
10. American Association for pediatric Ophthalmology and Strabismus (2019) San Francisco, United States.
11. Brody JA (1970) Hereditary blindness among Pingelapese people of Eastern Caroline Islands. Lancet 295(7659): 1253-1257.
12. Hussels IE (1972) Pingelap and Mokil Atolls: achromatopsia. Am J Hum Genet 24(3): 304-309.
13. Morton NE (1972) Pingelap and Mokil Atolls: historical genetics. Am J Hum Genet 24(3): 277-289.
14. Sundin OH (2000) Genetic basis of total colour blindness among the Pingelapese islanders. Nat Genet 25(3): 289-293.
15. Molday RS, Moritz OL (2015) Photoreceptors at a glance. Journal of Cell Science 128: 4039-4045.
16. Kazilek CJ, Cooper K (2010) Rods and Cones of the Human Eye. ASU, Ask A Biologist.
17. Longstaff A (2011) BIOS Instant Notes in Neuroscience. (3rd edn.) London, United Kingdom.
18. Williamson SJ, Cummins HZ (1983) Light and Color in Nature and Art. New York, USA.
19. Ahnelt PK, Kolb H, Pfürg R (1987) Identification of a subtype of cone photoreceptor, likely to be blue sensitive, in the human retina. J Comp Neurol 255: 18-34.
20. Ahnelt PK, Keri C, Kolb H (1990) Identification of pedicles of putative blue sensitive cones in human and primate retina. J Comp Neurol 293(1): 39-53.
21. (2015) Cooper Vision. All the Different Kinds of Color Blindness.
22. (2006) Tiresias.org. Guidelines: Color Blindness.
23. Cassin B, Solomon S (1990) Dictionary of Eye Terminology. Gainsville, Florida: Triad Publishing Company.
24. Pokorny J, Smith VC, Pinckers AJ, Cosjens M (1982) Classification of complete and incomplete autosomal recessive achromatopsia. Graefes Arch Exp Ophthalmol 219(3): 121-130.
25. Michaeilides M, Hunt DM, Moore AT (2004) The cone dysfunction syndromes. Br J Ophthalmol 88(2): 291-297.
26. Komáří AM (2016) Emerging Treatments for Achromatopsia. Retinal Physician (13)46-56.
27. Enchroma Types of Colour Blindness.
28. Colour Blind Awareness. Types of Colour Blindness Nd.
29. Jordan G, Mollon J (2019) Tetrachromacy: the mysterious case of extraordinary color vision. Behavioral Sciences 30: 130-134.
30. New World Encyclopedia. Cone Cell Nd.
31. Robinson J, Schmitt EA, Harosi FI, Harosi RJ, Dowling JE (1993) Zebrafish ultraviolet visual pigment: Absorption spectrum, sequence and localization. Proc Natl Acad Sci 90(13): 6009-6012.
32. Remington LA, Goodwin D (2012) Clinical Anatomy and Physiology of the Visual System. (3rd edn.) St. Louis: Elsevier/Butterworth-Heinemann.
33. Arashkysky VV, Burns ME (2012) Photoreceptor signaling: supporting vision across a wide range of light intensities. J Biol Chem 287(3): 1620-1626.
34. Lamb TD, Pugh EN (2006) Phototransduction, dark adaptation, and rhodopsin regeneration the prcotor lecture. Invest Ophthalmol Vis Sci 47(12): 5138-5152.
35. Luo DG, Xue T, Yao KW (2008) How vision begins: an odyssey. Proc Natl Acad Sci 105(29): 9855-9862.
36. Palczewski K (2014) Chemistry and biology of the initial steps in vision: The Friedenwald lecture. Invest Ophthalmol Vis Sci 55(10): 6651-6672.
37. Arashkysky, Vadin Y, Lamb, Trevor D, Pugh, et al. (2002) G Proteins and Phototransduction. Annual Review of Physiology 64(1): 153-187.
38. Burns ME, Pugh EN (2010) Lessons from photoreceptors: turning off G-protein signaling in living cells. Physiology (Bethesda) 25(2): 72-84.
39. Korenbliton J (2012) Speed, sensitivity, and stability of the light response in rod and cone photoreceptors: facts and models. Prog Retin Eye Res 31(5): 442-66.
40. Pugh EN, Lamb TD (1993) Amplification and kinetics of the activation steps in phototransduction. Biochem. Biophys. Acta 1141(2-3): 111-49.
41. Leskov IB, Klendkin VA, Hardly JW, Whitlock GG, Govardovskii VI, et al. (2000) The Gain of Rod Phototransduction: Reconciliation of Biochemical and Electrophysiological Measurements. Neuron 27(3): 525-537.
42. Farjo KM, Moiseyev G, Takahashi Y, Crouch RK, Ma JX (2009) The 11-cis-retinol dehydrogenase activity of RDH10 and its interaction with visual cycle cyprins. Invest Ophthalmol Vis Sci 50(11): 5089-5097.
43. Thompson DA, Janecke AR, Lange J (2005) Retinal degeneration associated with RDH11 mutations results from decreased 11-cis retinal synthesis due to disruption of the visual cycle. Hum Mol Genet 14(24): 3865-3875.
44. Bartolomeo P, Bachoud-Lévi AC, Thiebaut MS (2014) The Anatomy of Cerebral Achromatopsia: A Reappraisal and Comparison of Two Case Reports. Cortex Elsevier 56: 130-144.
45. Setäli K, Vesti E (1993) Acquired cerebral achromatopsia: A case report. Journal Neuro-Ophthalmology 14: 31-36.
46. Kohl S, Marx T, Giddings I (1998) Total colourblindness is caused by mutations in the gene encoding the α-subunit of the cone photoreceptor cGMP-gated cation channel. Nat Genet 19: 257-259.
47. Kohl S, Zobor D, Chiang WC (2015) Mutations in the unfolded protein response regulator ATF6 cause the cone dysfunction disorder achromatopsia. Nat Genet 47(7): 757-759.
48. Kohl S, Varsanyi B, Antunes GA (2005) CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia. Eur J Hum Genet 13(3): 302-308.
49. Wissinger B, Gerner D, Jagle H, Giorda R, Marx T, et al. (2001) CNGA3 mutations in hereditary cone photoreceptor disorders. Am J Hum Genet 69(4): 722-37.
50. Kohl S, Baumann B, Brnghammer M, Jagle H, Sieving P, et al. (2000) Mutations in the CNGB3 gene encoding the beta-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia (ACHM3) linked to chromosome 8q21. Hum Mol Genet 9: 2107-2116.
51. Sundin OH, Yang JM, Li Y, Zhu D, Hurd JN, et al. (2000) Genetic basis of total colorblindness among the Pingelapese islanders. Nat Genet 25(3): 289-293.
52. Rojas CV, Maria LS, Santos JL, Cortes F, Allende MA (2002) A frameshift insertion in the cone cyclic nucleotide gated cation channel causes complete achromatopsia in a consanguineous family from a rural isolate. Eur J Hum Genet 10(10): 639-642.
53. DingXQ, Matveeva A, Singh A, Komori N, Matsumoto H (2012) Biochemical characterization of cone cyclic nucleotide-gated (CNG) channel using the infrared fluorescence detection system. Adv Exp Med Biol 723: 769-775.
54. Shuart NG, Haifin Y, Camp SS, Black KD, Zagotta WN (2011) Molecular mechanism for 3:1 subunit stoichiometry of rod cyclic nucleotide-gated ion channels. Nat Commun 2: 457.
55. Kohl S, Coppeters E, Meire F, Sjaech S, Roosing S, et al. (2012) A nonsense mutation in PDE6H causes autosomal-recessive incomplete achromatopsia. Am J Hum Genet 91(3): 527-532.
56. Alligianis IA, Forshew T, Johnson S, Michaeilides M, Johnson CA, et al. (2002) Mapping of a novel locus for achromatopsia (ACHM4) to 1p and identification of a germline mutation in the alpha subunit of cone transducin (GNAT2). J Med Genet 39(9): 665-660.
57. Thiadens AA, den Hollander AI, Roosing S, Nabauws SB, Zekveld-Vroon RG, et al. (2009) Homozygosity mapping reveals PDE6C mutations in patients with early-onset cone photoreceptor disorders. Am J Hum Genet 85(2): 240-247.

58. Chang B, Grau T, Dangel S, Hurd R, Jurkles B, et al. (2009) A homologous genetic basis of the murine cpfl mutant and human achromatopsia linked to mutations in the PDE6C gene. Proc Natl Acad Sci U S A 106(46): 19581-19586.

59. Grau T, Artemyev NO, Rosenberg T, Dollfus H, Haugen OH, et al. (2011) Decreased catalytic activity and altered activation properties of PDE6C mutants associated with autosomal recessive achromatopsia. Hum Mol Genet 20: 719-730.

60. Kohl S, Varsanyi B, Autunes GA (2005) CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia. Eur J Hum Genet 13(3): 302-308.

61. Futterman F (2005) What Is Achromatopsia? 1997-2008.

62. Sundaram V, Wilde C, Aboshia J (2014) Retinal structure and function in achromatopsia: implications for gene therapy. Ophthalmology 121(1): 234-245.

63. Remmer MH, Rastogi N, Ranka MP, Ceiker EJ (2015) Achromatopsia: a review. Curr Opin Ophthalmol 26(5): 333-340.

64. Pascual Camps I, Barranco Gonzalez H, Aviño Martínez J, Silva E, Harto Castañó M (2018) Diagnosis and Treatment Options for Achromatopsia: A Review of the Literature. J Pediatr Ophthalmol Strabismus 55(2): 85-92.

65. Sharpe LT, Stockman A, Jagle H, Nathans J (1999) Opsin genes, cone photopigments, color vision, and color blindness. In: Gengenbauer K, Sharpe LT (Eds.), Color Vision: from Genes to Perception Cambridge University Press Cambridge, UK, p.3-52.

66. Kohl S, Jagle H, Wissinger B (2004) Achromatopsia. In: Adam MP, Ardringen HH, Pagon RA (Eds.), GeneReviews. Seattle, Wa: University of Washington, Seattle 1993-2017.

67. Whatham AR, Nguyen V, Zhu Y, Hennessy M, Kalloniatis M (2014) The value of clinical electrophysiology in the assessment of the eye and visual system in the era of advanced imaging. Clin Exp Optom 92: 99-115.

68. Young B, Eggen Berger E, Kaufman D (2012) Current electrophysiology in ophthalmology: a review. Curr Opin Ophthalmol 23(6): 497-505.

69. Genead MA, Fishman GA, Rha J (2011) Photoreceptor structure and function in patients with congenital achromatopsia. Invest Ophthalmol Vis Sci 52: 7298-7308.

70. Thomas MG, McLean RJ, Kohl S, Sheth V, Gottlob I (2012) Early signs of longitudinal progressive cone photoreceptor degeneration in achromatopsia. Br J Ophthalmol 96: 1232-1236.

71. Thiadens AA, Somervuo V, van den Born LI, Roosing S, van Snoeijen MJ (2010) Progression loss of cones in achromatopsia: an imaging study using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 51(11): 5952-5957.

72. Thomas MG, Kumar A, Kohl S, Proudlock FA, Gottlob I (2011) High-resolution in vivo imaging in achromatopsia. Ophthalmology 118: 882-887.

73. Greenberg JP, Sherman J, Zweifel SA, Chen RW, Duncker T (2014) Spectral-domain optical coherence tomography staging and autofluorescence imaging in achromatopsia. JAMA Ophthalmol 132(4): 437-445.

74. Scoles D, Sulai YN, Langlo CS, Fishman GA, Curcio CA (2014) In vivo imaging of human cone photoreceptor inner segments. Invest Ophthalmol Vis Sci 55: 4244-4251.

75. Carroll J, Choi SS, Williams DR (2008) In vivo imaging of the photoreceptor mosaic of a rod monochromat. Vision Res 48(26): 2564-2568.

76. Aboshia J, Dubis AM, Cowing J, Fahy RT, Sundaram V, et al. (2014) A prospective longitudinal study of retinal structure and function in achromatopsia. Invest Ophthalmol Vis Sci 55(9): 5733-5743.

77. Dubis AM, Cooper RF, Aboshia J, Langlo C, Sundaram V, et al. (2014) Genotype-dependent variability in residual cone structure in achromatopsia: towards developing metrics for assessing cone health. Invest Ophthalmol Vis Sci 55: 7303-7311.

78. Lee H, Purohit R, Sheth V, McLean RJ, Kohl S, et al. (2015) Retinal development in infants and young children with achromatopsia. Ophthalmology 122: 2145-2147.

79. Zobor D, Werner A, Stanzal F, Benedicenti F, Rudolph G, et al. (2017) The clinical phenotype of CNGA3-related achromatopsia: pretreatment characterization in preparation of a gene replacement therapy trial. Invest Ophthalmol Vis Sci 58(2): 821-832.

80. Fahlmann AT, Khan NW, Zahid S (2013) Diagnostic fundus autofluorescence patterns in achromatopsia. Am J Ophthalmol115(6): 1211-1219.

81. Li FF, Huang XF, Chen J (2015) Identification of novel mutations by targeted exome sequencing and the genotype-phenotype assessment of patients with achromatopsia. J Transl Med 13: 334.

82. Schornack MM, Brown WL, Siemens DW (2007) The use of tinted contact lenses in the management of achromatopsia. Optometry 78: 17-22.

83. Park WL, Sunness JS (2004) Red contact lenses for alleviation of photophobia in patients with conediscorders. Am J Ophthalmol137: 774-775.

84. Fonda G, Thomas H (1974) Correction of low visual acuity in achromatopsia. Use of corrective lenses as aid to educational and vocational placement. Arch Ophthalmol 91: 20-23.

85. Zobor D, Zobor G, Kohl S (2015) Achromatopsia: On the Doorstep of a Possible Therapy. Ophthalmic Res 54: 103-108.

86. Roosing S, Thiadens AA, Hoyng CB, Klaver CC, den Hollander AI, et al. (2014) Causes and consequences of inherited cone disorders. Prog Retin Eye Res 42: 1- 26.

87. 2020 Ludwig Maximilian University of Munich. New gene therapy for complete color blindness tested in patients. Medical Xpress.

88. Hardy R (2020) Gene therapy for color blindness passes first phase of human testing. New Atlas.

89. Spade RF, Curcio CA (2011) Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. Retina 31(8): 1609-1619.

90. Jonnal RS, Kocagolu OP, Zavazdski RJ, Lee SH, Werner JS, et al. (2014) The cellular origins of the outer retinal bands in optical coherence tomography images. Invest Ophthalmol Vis Sci 55(12): 7904-7918.

91. Dubra A, Sulai Y, Norris JL (2011) Noninvasive imaging of the human rod photoreceptor mosaic using a confocal adaptive optics scanning ophthalmoscope. Biomed Opt Express 2(7): 1864-1876.

92. Roorda A, Duncan JL (2015) Adaptive optics ophthalmoscopy. Annu Rev Vis Sci 1: 19-50.

93. Roorda A, Williams DR (2002) Optical fiber properties of individual human cones. J Vis 2(5): 404-412.

94. Kohl S, Baumann B, Broghammer M (2002) Mutations in the cone photoreceptor α-subunit gene GNAT2 in patients with achromatopsia. Am J Hum Genet 71(2): 422-425.

95. Felden J, Baumann B, Ali M (2019) Mutation spectrum and clinical phenotype of CNGA3-related achromatopsia: pretreatment characterization in preparation of a gene replacement therapy trial. Invest Ophthalmol Vis Sci 58(2): 821-832.

96. Weisschu N, Stingl K, Audo I (2018) Mutations in the gene PDE6C encoding the catalytic subunit of the cone photoreceptor phosphodiesterase in patients with achromatopsia. Hum Mutat 39: 1366-1371.
97. Ansar M, Santos Cortez RL, Saqib MA (2015) Mutation of ATF6 causes autosomal recessive achromatopsia. Hum Genet 134(9): 941-950.

98. Skorcyzk Werner A, Chiang WC, Wawrocka C (2017) Autosomal recessive cone-rod dystrophy can be caused by mutations in the ATF6 gene. Eur J Hum Gen 25(11): 1210-1216.

99. Michaelides M, Hunt DM, Moore AT (2004) The cone dysfunction syndromes. Br J Ophthalmol 88(2): 291-297.

100. Andréasson S, Tornqvist K (1991) Electroretinograms in patients with achromatopsia. Acta Ophthalmol 69(6): 711-716.

101. Johnson S (2004) Achromatopsia caused by novel mutations in both CNGA3 and CNGB3. J Med Genet 41(2): e20.

102. Georgiou M, Litts KM, Katitzeos A (2019) Adaptive optics retinal characterization, interocular symmetry, and intrafamilial variability. Invest Ophthalmol Vis Sci 60(13): 383-396.

103. Hirji N, Aboshiba J, Georgiou M, Bainbridge J, Michaelides M (2018) Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options. Ophthalmic Genet 39(2): 149-157.

104. Wissinger B, Schaich S, Baumann B, Bonin M, Jägle H, et al. (2011) Large deletions of the KCNV2 gene are common in patients with cone dystrophy with supernormal rod response. Hum Mutat 32(12): 1398-1406.

105. Komaromy AM, Rowland JS, Corr AT, Reinstein SL, Boye SL, et al. (2013) Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia. Mol Ther 21(6): 1131-1141.

106. Mastey RR, Georgiou M, Langlo CS (2019) Characterization of retinal structure in ATF6-associated achromatopsia. Invest Ophthalmol Vis Sci 60(7): 2631-2640.

107. Ueno S, Nakanishi A, Kominami T (2017) In vivo imaging of a cone mosaic in a patient with achromatopsia associated with a GNAT2 variant. Jpn J Ophthalmol 61: 92-98.